AI 의료 진단 앱 시장 : 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the AI medical diagnosis app market size is expected to grow from USD 3.81 million in 2025 to USD 4.48 million in 2026 and is forecast to reach USD 10.38 million by 2031 at 18.30% CAGR over 2026-2031.

This report is Segmented by Component (Software, Hardware, Services), Application (In Vivo Diagnostics, in Vitro Diagnostics), Deployment Mode (Cloud Based, Hybrid, On Premises), End User (Hospitals, Diagnostic Imaging Centers, Diagnostic Laboratories, Clinics and Other Healthcare Providers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).

Global AI Medical Diagnosis App Market Trends and Insights

Rising Demand for Faster Triage and Early Disease Detection

The AI medical diagnosis app market is benefiting from hospital demand for faster reading, earlier flagging, and better front-end prioritization in overloaded imaging workflows. Aidoc received FDA Breakthrough Device Designation in June 2026 for First Read, an autonomous tool that generates preliminary chest radiograph reports, which shows that AI medical diagnosis app market adoption is moving beyond alerting into direct reporting support. A 2026 study in BMC Medical Imaging found that an AI-integrated structured reporting tool for coronary CT angiography reduced reporting time by 40.2% and improved inter-reader agreement from 45.3% to 94.6%, which supports faster output without weakening consistency . Hospitals facing staffing shortages are therefore more willing to evaluate systems that shorten turnaround time and help clinicians focus on urgent cases first. This pattern is helping the AI medical diagnosis app market move toward use cases where time savings and operational relief are visible at the department level soon after deployment.

Expansion of AI-Enabled Radiology and Pathology Workflow

The AI medical diagnosis app market continues to build on radiology because imaging remains the most mature clinical area for regulatory clearances, deployment experience, and dataset availability. Siemens Healthineers and Mayo Clinic expanded their collaboration in February 2026 to develop AI-enabled MRI protocols for neurodegenerative disease, prostate cancer, and metastatic liver tumor management, which shows how vendors are embedding AI inside imaging workflows rather than selling it as a separate layer. GE HealthCare's Photonova Spectra photon-counting CT received FDA 510(k) clearance in March 2026 and integrates NVIDIA accelerated computing that handles up to 50 times more data than conventional CT, which strengthens routine AI-based quantitative analysis in daily imaging practice. In pathology, vendors such as Paige and Ibex are pushing tissue AI into clinical workflows, which is expanding the AI medical diagnosis app market beyond radiology and into diagnostic processes with high review volume and clear automation needs. As AI becomes part of scanner protocols and diagnostic systems, buyers face deeper vendor dependence over multiyear equipment cycles, and that raises switching barriers in the AI medical diagnosis app market.

Algorithm Explainability and Liability Concerns Slow Clinical Adoption

The AI medical diagnosis app market is advancing faster than the governance systems that decide accountability when an algorithm influences a clinical decision . A JAMA Network Open study reviewing FDA-authorized AI-enabled medical devices noted that all implantable AI devices in its sample cleared through the 510(k) pathway, which raises questions around the depth of clinical evidence and legal responsibility when errors occur. The EU AI Act classifies many medical diagnostic applications as high-risk systems, and the phased compliance burden will require stronger post-market monitoring, human oversight, and transparency processes from vendors. A 2026 review available through PMC also noted that continuous learning models create accountability gaps because post-deployment updates do not fit neatly into older surveillance structures. As a result, enterprise buying cycles in the AI medical diagnosis app market can lengthen when legal, ethics, and compliance teams want stronger proof of model behavior, update control, and failure response.

Other drivers and restraints analyzed in the detailed report include:

1. Multi-Modal Clinical Data Convergence Improves Diagnostic Precision
2. Provider Push Toward Workflow Automation in Overloaded Systems

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Software held 65.2% of AI medical diagnosis app market share in 2025, and it is also projected to grow at an 18.8% CAGR through 2031. This lead reflects the economics of licensing and subscription models, where incremental distribution is easier than for hardware-heavy systems in the AI medical diagnosis app market. Google released MedGemma 1.5 in 2026, and NVIDIA expanded medical imaging support through NIM microservices, which helps software vendors shorten the path from model development to deployable products. As a result, software remains the clearest scale engine inside the AI medical diagnosis app industry because it combines regulatory reuse, update flexibility, and recurring revenue potential.

Hardware still matters because AI-enabled scanners and accelerated edge systems raise the quality and speed of inference during routine use. GE HealthCare's Photonova Spectra shows this role clearly because the system supports GPU-based reconstruction and high-volume data handling at the imaging layer. Services form the third component block, and this part of the AI medical diagnosis app market will stay relevant as providers need validation, implementation, monitoring, and compliance support after deployment. Regulatory demands in China and Europe are also increasing the need for lifecycle management and post-market oversight, which supports a steady services opportunity across the AI medical diagnosis app industry.

In vivo diagnostics represented 63.8% share of the AI medical diagnosis app market size in 2025, which keeps imaging at the center of current commercial demand. Radiology reached adoption earlier than most specialties because it had clearer regulatory precedents, large labeled datasets, and stronger workflow fit for automation in the AI medical diagnosis app market. Qure.AI had 26 FDA-cleared indications across 9 products by February 2026, which shows how regulatory depth in imaging can support broad deployment across screening and hospital settings. This keeps in vivo diagnostics ahead on installed use, customer familiarity, and near-term revenue capture.

In vitro diagnostics is smaller today, but it is projected to grow at a 5.2% CAGR through 2031 as machine learning expands into immunoassay, molecular diagnostics, and digital pathology workflows. The draft notes that AI-enabled microfluidic platforms can support self-correcting lab-on-chip systems that compare outputs to training data in real time, which strengthens automation at the point of care. Roche's planned acquisition of PathAI also shows that large diagnostics companies now view AI pathology and image management as core assets rather than optional extensions. Over time, the AI medical diagnosis app market should see a more balanced application mix as laboratory automation and pathology software move closer to imaging in commercial relevance.

Complete Report Scope:

• By Component
  • Software
  • Hardware
  • Services
• By Application
  • In Vivo Diagnostics
  • In Vitro Diagnostics
• By Deployment Mode
  • Cloud Based
  • Hybrid
  • On Premises
• By Tend User
  • Hospitals
  • Diagnostic Imaging Centers
  • Diagnostic Laboratories
  • Clinics and Other Healthcare Providers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 55.1% of AI medical diagnosis app market share in 2025, which keeps it as the largest regional block in the AI medical diagnosis app market. This position is supported by a strong FDA clearance environment, high IT readiness, and provider budgets that can absorb enterprise-scale software deployment. Aidoc received FDA Breakthrough Device Designation for First Read in June 2026, and that kind of regulatory acceleration supports faster commercialization for vendors addressing urgent clinical workflows. Private capital also remains active in the region, as Aidoc raised USD 150 million in April 2026, which signals continued investor confidence in near-term clinical AI monetization in the AI medical diagnosis app market.

Europe has a different profile because growth is tied closely to compliance readiness, hospital digitization, and system-level procurement rules in the AI medical diagnosis app market. The EU AI Act and GDPR create a stricter operating environment for health data and high-risk software, which tends to favor vendors with established filings and stronger documentation capacity. The UK's NHS has also shown that AI can reduce mammography screening workloads, and this keeps imaging use cases prominent in regional procurement discussions. Germany remains important because of its medical technology base and hospital purchasing depth, while France, Italy, and Spain offer expansion potential as digitization programs support EHR and PACS modernization.

Asia Pacific is projected to record the fastest CAGR at 19.2% through 2031 in the AI medical diagnosis app market. The region is benefiting from policy support, domestic AI vendors, and large unmet diagnostic demand across both advanced and emerging healthcare systems. South Korea reported 157 medical AI approvals in 2025 and issued the first clearance of a generative AI medical device in April 2026, which shows an active regulatory environment for newer software categories. Japan is also updating SaMD guidance, while India and Southeast Asia are expanding deployment in under-resourced settings through models tied to portable imaging and public health programs. The Middle East and Africa are growing from a smaller base through smart hospital investment and public partnerships, while South America is being supported by hospital group consolidation and broader private insurance reach.

1. Alphabet Inc. (Google Health / DeepMind)
2. Microsoft
3. NVIDIA
4. Siemens Healthineers
5. GE HealthCare Technologies Inc.
6. Koninklijke Philips
7. Roche
8. Tempus AI, Inc.
9. Aidoc Medical Ltd.
10. Qure.AI Technologies Private Limited
11. Heartflow
12. PathAI, Inc.
13. Paige.AI, Inc.
14. IBM
15. Ada Health GmbH
16. AliveCor
17. Butterfly Network, Inc.
18. Digital Diagnostics
19. Lunit
20. Ibex Medical Analytics Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Demand for Faster Triage and Early Disease Detection
  • 4.2.2 Expansion of AI-Enabled Radiology and Pathology Workflows
  • 4.2.3 Multi-Modal Clinical Data Convergence Improves Diagnostic Confidence
  • 4.2.4 Provider Push Toward Workflow Automation in Overburdened Health Systems
  • 4.2.5 Integration With Wearables and Remote Monitoring Expands Diagnostic Reach
  • 4.2.6 Growing Investment in Clinical Validation and Interoperable AI Platforms
• 4.3 Market Restraints
  • 4.3.1 Algorithm Explainability and Liability Concerns Slow Clinical Trust
  • 4.3.2 High Integration Cost Across PACS, EHR, and Hospital IT Stacks
  • 4.3.3 Data Privacy, Sovereignty, and Cross-Border Model Training Constraints
  • 4.3.4 Regulatory Heterogeneity and Revalidation Burden for Model Updates
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces

5 Market Size & Growth Forecasts (Value; volume for key analytes)

• 5.1 By Component
  • 5.1.1 Software
  • 5.1.2 Hardware
  • 5.1.3 Services
• 5.2 By Application
  • 5.2.1 In Vivo Diagnostics
  • 5.2.2 In Vitro Diagnostics
• 5.3 By Deployment Mode
  • 5.3.1 Cloud Based
  • 5.3.2 Hybrid
  • 5.3.3 On Premises
• 5.4 By Tend User
  • 5.4.1 Hospitals
  • 5.4.2 Diagnostic Imaging Centers
  • 5.4.3 Diagnostic Laboratories
  • 5.4.4 Clinics and Other Healthcare Providers
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.4.6 Rest of Europe
  • 5.5.5 Asia-Pacific
    • 5.5.5.1 China
    • 5.5.5.2 India
    • 5.5.5.3 Japan
    • 5.5.5.4 South Korea
    • 5.5.5.5 Australia
    • 5.5.5.6 Rest of Asia-Pacific
  • 5.5.6 Middle East & Africa
    • 5.5.6.1 GCC
    • 5.5.6.2 South Africa
    • 5.5.6.3 Rest of Middle East and Africa
  • 5.5.7 South America
    • 5.5.7.1 Brazil
    • 5.5.7.2 Argentina
    • 5.5.7.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles
  • 6.3.1 Alphabet Inc. (Google Health / DeepMind)
  • 6.3.2 Microsoft Corporation
  • 6.3.3 NVIDIA Corporation
  • 6.3.4 Siemens Healthineers AG
  • 6.3.5 GE HealthCare Technologies Inc.
  • 6.3.6 Koninklijke Philips N.V.
  • 6.3.7 F. Hoffmann-La Roche Ltd
  • 6.3.8 Tempus AI, Inc.
  • 6.3.9 Aidoc Medical Ltd.
  • 6.3.10 Qure.ai Technologies Private Limited
  • 6.3.11 Heartflow, Inc.
  • 6.3.12 PathAI, Inc.
  • 6.3.13 Paige.AI, Inc.
  • 6.3.14 IBM Corporation
  • 6.3.15 Ada Health GmbH
  • 6.3.16 AliveCor, Inc.
  • 6.3.17 Butterfly Network, Inc.
  • 6.3.18 Digital Diagnostics, Inc.
  • 6.3.19 Lunit Inc.
  • 6.3.20 Ibex Medical Analytics Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White Space and Unmet Need Assessment